Trial Profile
Efficacy and safety of infliximab biosimilar (CT-P13) in patients with rheumatoid arthritis: Real-life setting in Korea
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Jul 2017
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- 06 Jul 2017 New trial record
- 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism